$\require{mediawiki-texvc}$
  • 검색어에 아래의 연산자를 사용하시면 더 정확한 검색결과를 얻을 수 있습니다.
  • 검색연산자
검색연산자 기능 검색시 예
() 우선순위가 가장 높은 연산자 예1) (나노 (기계 | machine))
공백 두 개의 검색어(식)을 모두 포함하고 있는 문서 검색 예1) (나노 기계)
예2) 나노 장영실
| 두 개의 검색어(식) 중 하나 이상 포함하고 있는 문서 검색 예1) (줄기세포 | 면역)
예2) 줄기세포 | 장영실
! NOT 이후에 있는 검색어가 포함된 문서는 제외 예1) (황금 !백금)
예2) !image
* 검색어의 *란에 0개 이상의 임의의 문자가 포함된 문서 검색 예) semi*
"" 따옴표 내의 구문과 완전히 일치하는 문서만 검색 예) "Transform and Quantization"

과학기술 지식인프라 ScienceON

상세검색 다국어 입력
도움말도움말
쳇봇 이모티콘
안녕하세요!
ScienceON 챗봇입니다.
궁금한 것은 저에게 물어봐주세요.

논문 상세정보

MyON담기
내보내기

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma

Journal of Korean medical science : JKMS v.20 no.4 = no.104 , 2005년, pp.598 - 602  
Lee, Keun-Wook (Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Yun, Tak ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Song, Eun Kee ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Na, Im il ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Shin, Hyunchoon ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Bang, Soo-Mee ( Department of Internal Medicine, Gachon Medical School, Incheon, Korea. ) ;  Lee, Jae Hoon ( Department of Internal Medicine, Gachon Medical School, Incheon, Korea. ) ;  Lee, Seung Tae ( Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. ) ;  Kim, Jee Hyun ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Yoon, Sung-Soo ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. ) ;  Lee, Jong Seok ( Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea) ;  Park, Seonyang ;  Kim, Byoung Kook ;  Kim, Noe Kyeong
Abstract

Recent clinical trials showed that bortezomib, a novel proteasome inhibitor, had therapeutic activity in multiple myeloma. However, there was no data about the feasibility of bortezomib in Korean patients. We performed a pilot study of bortezomib in patients with relapsed or refractory myeloma (1.3 mg/m2 twice weekly for 2 week in a 3-week cycle). Seven patients were enrolled. The median age of patients was 59 yr. All patients previously received VAD (vincristine, doxorubicin and dexamethasone) and thalidomide chemotherapy. Three patients previously received alkylator-containing chemotherapy and 4 patients, autologous stem cell transplantation. Bortezomib monotherapy resulted in 3 partial remissions (43%), 3 no changes (43%) and 1 progressive disease (14%). One patient who had no response to bortezomib monotherapy experienced partial remission after addition of dexamethasone to bortezomib. The most common serious toxicity was thrombocytopenia (grade 3/4, 10 of 20 cycles (50%)) and grade 3 peripheral neuropathy was developed in 2 of 20 cycles (10%). Drug-related adverse event led to discontinuation of bortezomib in 1 patient. There was no treatment related mortality. Overall, bortezomib seems to be effective and feasible. Conduction of larger clinical studies on Korean patients is necessary to characterize clinical efficacy and safety of bortezomib more precisely.

주제어

#Multiple Myeloma   #Drug Therapy   #bortezomib   #Velcade   #Proteasome Endopeptidase Complex   #Protease Inhibitors  

참고문헌 (0)

  1. 이 논문의 참고문헌 없음

이 논문을 인용한 문헌 (0)

  1. 이 논문을 인용한 문헌 없음

원문보기

원문 PDF 다운로드

  • 원문 PDF 정보가 존재하지 않습니다.

원문 URL 링크

원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다. (원문복사서비스 안내 바로 가기)

상세조회 0건 원문조회 0건

DOI 인용 스타일